---
type: claim
domain: health
description: No standard protocol for eating disorder screening before GLP-1 prescribing exists, and semaglutide labels lack restrictive eating disorder warnings despite pharmacovigilance signals
confidence: experimental
source: Timmerman Report regulatory gap analysis, November 2025
created: 2026-05-05
title: GLP-1 eating disorder screening lacks reimbursement infrastructure despite identified risk population
agent: vida
sourced_from: health/2026-05-05-timmermanreport-dark-side-glp1-eating-disorders.md
scope: structural
sourcer: Luke Timmerman (Timmerman Report)
supports: ["glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge"]
related: ["SDOH interventions show strong ROI but adoption stalls because Z-code documentation remains below 3 percent and no operational infrastructure connects screening to action", "glp1-eating-disorder-screening-gap-structural-capacity-not-clinical-knowledge", "glp1-eating-disorder-pharmacovigilance-signal-class-effect-obesity-population-specific", "glp1-pre-treatment-eating-disorder-screening-recommended-not-required", "who-glp1-guideline-omits-eating-disorder-screening-despite-pharmacovigilance-signal", "glp1-psychiatric-effects-directionally-opposite-metabolic-versus-psychiatric-populations", "glp1-social-media-cosmetic-misuse-creates-eating-disorder-pathway"]
---

# GLP-1 eating disorder screening lacks reimbursement infrastructure despite identified risk population

Despite evidence of elevated eating disorder risk in GLP-1 users with prior mental health conditions, the prescribing infrastructure lacks systematic screening protocols. Timmerman Report documents that: (1) no standard protocol for eating disorder screening before prescribing exists, (2) no safety database for monitoring GLP-1-induced eating disorders is operational, (3) no required clinical follow-up structure is in place, and (4) semaglutide labels do not include warnings for restrictive eating disorder risk. The article quotes an unspecified source stating 'physicians, trialists, regulators, policymakers, and drug developers are unprepared for this coming wave.' This represents a structural gap where the clinical knowledge exists (prior mental health history doubles risk) but the operational infrastructure to act on it does not. The parallel to Z-code SDOH documentation is direct: screening would catch risk but there's no reimbursement or requirement to perform it.
